Results of a safety, tolerability and pharmacokinetic phase I study of VCH-916, a novel polymerase inhibitor for HCV, following single ascending doses in healthy volunteers

被引：4

作者：

Proulx, L. ^{[1
]}

Bourgault, B. ^{[1
]}

Chauret, N. ^{[1
]}

Larouche, R. ^{[2
]}

Tanguay, M. ^{[2
]}

Thibert, R. ^{[1
]}

机构：

[1] ViroChem Pharma Inc, Laval, PQ, Canada

[2] Anapharm A PharmaNet Co, Montreal, PQ, Canada

来源：

JOURNAL OF HEPATOLOGY | 2008年 / 48卷

关键词：

D O I：

10.1016/S0168-8278(08)60856-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

854

引用

页码：S320 / S321

页数：2

共 50 条

[21] SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ASCENDING SINGLE ORAL DOSES OF CC-930, A NOVEL JNK INHIBITOR, IN HEALTHY SUBJECTS
Ye, Y.
Kong, L.
Assaf, M.
Liu, L.
Wu, A.
Choudhury, S.
Laskin, O.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S31 - S31
[22] A PHASE I STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE DOSES OF SUBLINGUALLY ADMINISTERED ASENAPINE IN HEALTHY MALE VOLUNTEERS
Dogterom, P.
Timmer, C.
de Greef, R.
Spaans, E.
de Vries, D.
Peeters, P.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S86 - S87
[23] PHASE I STUDY IN HEALTHY VOLUNTEERS AND PATIENTS WITH IDX375, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR
de Bruijne, Joep
de Rooij, Jeroen van de Wetering
van Vliet, Andre A.
Leempoels, Jos
Zhou, Xiao-Jian
Weegink, Christine J.
Molenkamp, Richard
Schinkel, Janke
Temam, Marie-Francoise
Molles, Jeffrey
Chen, Jie
Pietropaolo, Keith
Sullivan-Bolyai, John
Mayers, Douglas L.
Reesink, Hendrik W.
HEPATOLOGY, 2010, 52 (04) : 1219A - 1219A
[24] A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled GDC-0214, a JAK1 Inhibitor, as Single- and Multiple-Ascending Doses in Healthy Volunteers
Owen, Ryan
Galanter, Joshua
Zhu, Rui
Cai, Fang
Tom, Jennifer
Wynne, Chris
Durk, Matthew
Chen, Liuxi
Kenny, Jane
She, Gao-hong
Vadhavkar, Shweta
Hwang, Olivia
Chen, Hubert
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB17 - AB17
[25] Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
Yap, Desmond Y. H.
Hai, Jojo
Lee, Paul C. H.
Zhou, Xueying
Lee, Michael
Zhang, Yu
Wang, Meng
Chen, Xiaoxiang
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (05): : 1769 - 1779
[26] Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers
Liang, Beibei
Wang, Jin
Bai, Nan
Chi, Yulong
Wang, Rui
Cai, Yun
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (10): : 1184 - 1190
[27] Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
Zou, Chan
Zuo, Xiaocong
Huang, Jie
Hua, Ye
Yang, Shuang
Yang, Xiaoyan
Guo, Can
Tan, Hongyi
Chen, Jun
Chu, Zhaoxing
Pei, Qi
Yang, Guoping
FRONTIERS IN PHARMACOLOGY, 2019, 10
[28] Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers
Mariotti, Fabrizia
Govoni, Mirco
Lucci, Germano
Santoro, Debora
Nandeuil, Marie Anna
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 3399 - 3410
[29] Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects
Kirby, Brian J.
Aranda, Richard
Ward, Renee
Steinberg, Marcos W.
Hernandez, Maria
Sosa, Judith
Cravets, Matt
Rose, Mark J.
Osterhout, Robin
Ding, Zhaoqing
Yusuf, Isharat
Fox, Judith
Mathias, Anita
BLOOD, 2022, 140 : 11570 - 11571
[30] Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy SubjectsA Randomized, Double-Blind, Placebo-Controlled, Phase I Study
Michael Derks
Judith Anzures-Cabrera
Lynn Turnbull
Mary Phelan
Clinical Drug Investigation, 2011, 31 : 325 - 335

← 1 2 3 4 5 →